Cargando…

Development of Therapeutic Vaccines for Ovarian Cancer

Ovarian cancer remains the deadliest of all gynecologic malignancies. Our expanding knowledge of ovarian cancer immunology has allowed the development of therapies that generate systemic anti-tumor immune responses. Current immunotherapeutic strategies include immune checkpoint blockade, cellular th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chow, Stephanie, Berek, Jonathan S., Dorigo, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711901/ https://www.ncbi.nlm.nih.gov/pubmed/33167428 http://dx.doi.org/10.3390/vaccines8040657

Ejemplares similares

Immunotherapeutic approaches to ovarian cancer treatment
por: Chester, Cariad, et al.
Publicado: (2015)

ASCO 2019 meeting review
por: Diver, Elisabeth, et al.
Publicado: (2019)

Therapeutic targets and new directions for antibodies developed for ovarian cancer
por: Bax, Heather J., et al.
Publicado: (2016)

Advances of exosome in the development of ovarian cancer and its diagnostic and therapeutic prospect
por: Shen, Jiayu, et al.
Publicado: (2018)

The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13 918 patients
por: Chan, J K, et al.
Publicado: (2007)

ROS and miRNA Dysregulation in Ovarian Cancer Development, Angiogenesis and Therapeutic Resistance
por: Stieg, David C., et al.
Publicado: (2022)

Scope of nanotechnology in ovarian cancer therapeutics
por: Yallapu, Murali M, et al.
Publicado: (2010)

Therapeutic strategies in epithelial ovarian cancer
por: Kim, Ayako, et al.
Publicado: (2012)

Therapeutic Inducers of Apoptosis in Ovarian Cancer
por: Binju, Mudra, et al.
Publicado: (2019)

Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53
por: PARK, SEE-HYOUN G, et al.
Publicado: (2014)

Therapeutic Targeting of Collective Invasion in Ovarian Cancer
por: Moffitt, Laura, et al.
Publicado: (2019)

Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development
por: Liang, Jie, et al.
Publicado: (2021)

Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation
por: Hu, Theodore, et al.
Publicado: (2014)

Perspectives for therapeutic HPV vaccine development
por: Yang, Andrew, et al.
Publicado: (2016)

Development of therapeutic vaccines for the treatment of diseases
por: Tian, Yaomei, et al.
Publicado: (2022)

Extracellular Vesicles in the Development of Cancer Therapeutics
por: Sun, Haoyao, et al.
Publicado: (2020)

An Overview of Candidate Therapeutic Target Genes in Ovarian Cancer
por: Alexandrova, Elena, et al.
Publicado: (2020)

Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
por: McCloskey, Curtis W., et al.
Publicado: (2018)

Fatty Acid Metabolism in Ovarian Cancer: Therapeutic Implications
por: Yoon, Hyunho, et al.
Publicado: (2022)

Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells
por: Yang, Wookyeom, et al.
Publicado: (2021)

Therapeutic Progress in Ovarian Cancer, Testicular Cancer and the Sarcomas
Publicado: (1981)

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
por: Blass, Eryn, et al.
Publicado: (2021)

Aberrant MAPK Signaling Offers Therapeutic Potential for Treatment of Ovarian Carcinoma
por: Colic, Eva, et al.
Publicado: (2022)

Current progress in the development of prophylactic and therapeutic vaccines
por: Li, Tingting, et al.
Publicado: (2022)

Reinvigorating therapeutic cancer vaccines
por: Robles-Oteiza, Camila, et al.
Publicado: (2022)

A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancer
por: Kobayashi, Hiroshi, et al.
Publicado: (2023)

Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets
por: Xie, Kaipeng, et al.
Publicado: (2019)

Cancer Vaccines in Ovarian Cancer: How Can We Improve?
por: Martin Lluesma, Silvia, et al.
Publicado: (2016)

Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches
por: Palaia, Innocenza, et al.
Publicado: (2020)

The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer
por: Dion, Ludivine, et al.
Publicado: (2020)

Pathophysiological Role and Potential Therapeutic Exploitation of Exosomes in Ovarian Cancer
por: Shimizu, Aasa, et al.
Publicado: (2020)

The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer
por: Li, Xiaoduan, et al.
Publicado: (2017)

MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities
por: Chen, San-Nung, et al.
Publicado: (2019)

Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis
por: Kobayashi, Hiroshi, et al.
Publicado: (2022)

Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention
por: Buonaiuto, Roberto, et al.
Publicado: (2023)

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges
por: Szymanowski, Wojciech, et al.
Publicado: (2023)

Integrin Inhibitors as a Therapeutic Agent for Ovarian Cancer
por: Sawada, Kenjiro, et al.
Publicado: (2012)

A Current Review of Targeted Therapeutics for Ovarian Cancer
por: Campos, Susana M., et al.
Publicado: (2010)

Therapeutic cancer vaccines and combination immunotherapies involving vaccination
por: Nguyen, Trang, et al.
Publicado: (2014)

Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells
por: Vafadar, Asma, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g8f7pqnpi0onoo1ianhprco76s